Radiofrequency ablation: mechanisms and clinical applications
Jianhua Wu,
Zhiyuan Zhou,
Yuanwen Huang,
Xinyue Deng,
Siting Zheng,
Shangwen He,
Genjie Huang,
Binghui Hu,
Min Shi,
Wangjun Liao,
Na Huang
Affiliations
Jianhua Wu
Department of Oncology, Nanfang Hospital Southern Medical University Guangzhou Guangdong China
Zhiyuan Zhou
Department of Oncology, Nanfang Hospital Southern Medical University Guangzhou Guangdong China
Yuanwen Huang
Department of Oncology, Nanfang Hospital Southern Medical University Guangzhou Guangdong China
Xinyue Deng
Department of Oncology, Nanfang Hospital Southern Medical University Guangzhou Guangdong China
Siting Zheng
Department of Oncology, Nanfang Hospital Southern Medical University Guangzhou Guangdong China
Shangwen He
Department of Respiratory and Critical Care Medicine Chronic Airways Diseases Laboratory, Nanfang Hospital, Southern Medical University Guangzhou Guangdong China
Genjie Huang
Department of Oncology, Nanfang Hospital Southern Medical University Guangzhou Guangdong China
Binghui Hu
Department of Oncology, Nanfang Hospital Southern Medical University Guangzhou Guangdong China
Min Shi
Department of Oncology, Nanfang Hospital Southern Medical University Guangzhou Guangdong China
Wangjun Liao
Department of Oncology, Nanfang Hospital Southern Medical University Guangzhou Guangdong China
Na Huang
Department of Oncology, Nanfang Hospital Southern Medical University Guangzhou Guangdong China
Abstract Radiofrequency ablation (RFA), a form of thermal ablation, employs localized heat to induce protein denaturation in tissue cells, resulting in cell death. It has emerged as a viable treatment option for patients who are ineligible for surgery in various diseases, particularly liver cancer and other tumor‐related conditions. In addition to directly eliminating tumor cells, RFA also induces alterations in the infiltrating cells within the tumor microenvironment (TME), which can significantly impact treatment outcomes. Moreover, incomplete RFA (iRFA) may lead to tumor recurrence and metastasis. The current challenge is to enhance the efficacy of RFA by elucidating its underlying mechanisms. This review discusses the clinical applications of RFA in treating various diseases and the mechanisms that contribute to the survival and invasion of tumor cells following iRFA, including the roles of heat shock proteins, hypoxia, and autophagy. Additionally, we analyze the changes occurring in infiltrating cells within the TME after iRFA. Finally, we provide a comprehensive summary of clinical trials involving RFA in conjunction with other treatment modalities in the field of cancer therapy, aiming to offer novel insights and references for improving the effectiveness of RFA.